Administration of deoxyribonucleosides or inhibition of their catabolism as a pharmacological approach for mitochondrial DNA depletion syndrome.
about
Mitochondrial diseases caused by toxic compound accumulation: from etiopathology to therapeutic approachesToward a therapy for mitochondrial diseaseMPV17 Loss Causes Deoxynucleotide Insufficiency and Slow DNA Replication in MitochondriaEmerging therapies for mitochondrial disorders.Mitochondrial diseases: advances and issues.Emerging aspects of treatment in mitochondrial disorders.Mitochondrial Neurogastrointestinal Encephalomyopathy Caused by Thymidine Phosphorylase Enzyme Deficiency: From Pathogenesis to Emerging Therapeutic Options.Mitochondrial purine and pyrimidine metabolism and beyond.MtDNA-maintenance defects: syndromes and genes.The Deoxynucleoside Triphosphate Triphosphohydrolase Activity of SAMHD1 Protein Contributes to the Mitochondrial DNA Depletion Associated with Genetic Deficiency of Deoxyguanosine Kinase.Aberrant ribonucleotide incorporation and multiple deletions in mitochondrial DNA of the murine MPV17 disease model.Reply: DGUOK recessive mutations in patients with CPEO, mitochondrial myopathy, parkinsonism and mtDNA deletions.Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2 Deficiency.Mitochondrial diseases: the contribution of organelle stress responses to pathology.Combined use of Saccharomyces cerevisiae, Caenorhabditis elegans and patient fibroblasts leads to the identification of clofilium tosylate as a potential therapeutic chemical against POLG-related diseases.Towards a therapy for mitochondrial disease: an update
P2860
Q26801561-18C0DB18-7449-4D5F-9707-D76985072258Q28080024-2064DDBF-CDC8-427C-BE31-2E96790E4C42Q35892524-73BEE707-FA9C-4EC6-AEA4-9B8E88046C3FQ36967723-3573B064-E1E3-4B1C-B8FA-429CB24F1155Q37653002-F93582B0-17B4-47A6-BC50-10C5C92B2FEBQ38472989-A59AA3CD-71D3-4CAA-99AE-29AA4CFA843DQ38750535-901C05BF-DD24-477B-82FD-32A2D082E07CQ39025697-56D6DB9E-54DA-4019-B2B2-08913FBC5E4DQ40955181-6BFC0F07-0F7F-4479-AA01-108217CDE311Q41014443-26C8FB9F-BDC6-43BF-BA94-2EB5653F85CBQ47115693-F285B1CD-87AE-4CF1-B26B-26D58BF0FB69Q47922216-04768203-E82A-4266-BF80-C75754332477Q47945459-D143E1A7-AFF9-4C0D-9494-A0201E069C17Q47974129-9B26A2F6-56F9-41EA-B10A-97078729CC9AQ55033717-3E675F67-D880-4FCD-AAF3-D2A29657F8F5Q57293416-E5FBEE4C-B444-4673-B454-96B3ABA7C1C3
P2860
Administration of deoxyribonucleosides or inhibition of their catabolism as a pharmacological approach for mitochondrial DNA depletion syndrome.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Administration of deoxyribonuc ...... ndrial DNA depletion syndrome.
@en
Administration of deoxyribonuc ...... ndrial DNA depletion syndrome.
@nl
type
label
Administration of deoxyribonuc ...... ndrial DNA depletion syndrome.
@en
Administration of deoxyribonuc ...... ndrial DNA depletion syndrome.
@nl
prefLabel
Administration of deoxyribonuc ...... ndrial DNA depletion syndrome.
@en
Administration of deoxyribonuc ...... ndrial DNA depletion syndrome.
@nl
P2860
P50
P356
P1476
Administration of deoxyribonuc ...... ondrial DNA depletion syndrome
@en
P2093
Mauro Scarpelli
Michio Hirano
P2860
P304
P356
10.1093/HMG/DDT641
P577
2013-12-20T00:00:00Z